PRIDE III Prison Interventions and HIV Prevention Collaboration
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Quantitative surveys for prison OAT providers
Being 18 years or older
Being currently assigned and working as a probation OAT provider for a probation site
ECHO procedures
Disqualifiers
None
Trial design
Design model
Parallel
Treatments tested in this trial
Opioid Agonist Therapy
BehavioralOpioid Agonist Therapy (OAT) as HIV prevention
Treatment groups
300 Participants
are divided into 2 treatment groupsGroup A: Aim 1- ImplementationExperimental treatment 1 intervention
Group B: Aim 2- Scale-UpExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of participants receiving opioid agonist therapy (OAT)
Number of patients receiving opioid agonist therapy (OAT) per OAT site.
Time frame
baseline up to 4 yearsSecondary outcomes
1
Adherence to NIATx protocol
Adherence to NIATx protocol: using the NIATx fidelity scale, a 19-item assesment to measure adherence to the NIATx model on a 5-point scale from 1 (No evidence) to 5 (Extensive evidence).
Time frame
baseline up to 4 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Yale University
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov